ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 300
Higher Disease Activity In Psoriatic Arthritis Is Associated With Elevated Total Cholesterol and Triglycerides
Abstract Number: 301
Arthritis and Nail Involvement In Patients With Plaque-Type Psoriasis
Abstract Number: 302
Maintenance Of Efficacy and Safety Of Ustekinumab In Patients With Active Psoriatic Arthritis Despite Prior Conventional Nonbiologic and Anti-TNF Biologic Therapy:  1‑year Results Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Abstract Number: 303
Risk Of Cardiovascular Events In Patients With Psoriatic Arthritis, Psoriasis, and Rheumatoid Arthritis: A General Population-Based Cohort Study
Abstract Number: 304
Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance
Abstract Number: 305
Incidence of Herpes Zoster in Patients with Psoriatic Arthritis
Abstract Number: 306
Responsiveness To Change Of a Global Ultrasound Assessment Score In Psoriatic Arthritis Patients
Abstract Number: 307
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Abstract Number: 308
Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool
Abstract Number: 309
Diagnostic Delay Of Even More Than 6 Months Contributes To Poor Radiographic and Functional Outcome In Psoriatic Arthritis
Abstract Number: 310
Long-Term Safety and Tolerability Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Abstract Number: 311
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis and Current Skin Involvement (PALACE 3)
Abstract Number: 313
The DC-STAMP+IL17A+ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Abstract Number: 314
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Abstract Number: 315
Long Term Outcomes In Psoriatic Arthritis 2; A Prospective Multicentre Observational Study Of Work Disability In Psoriatic Arthritis: First Report Of The Clinical and Socioeconomic Associations Of Work Disability In Psoriatic Arthritis
Abstract Number: 316
Quantiferon-TB Test Can Be Usefull For Decision Of Anti-Tuberculosis Prophylaxis During Anti-TNF Treatment: Result Of Real Life
Abstract Number: 317
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Tender and Swollen Joint Counts In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Abstract Number: 318
Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
Abstract Number: 319
Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Abstract Number: 320
Sustained Improvement In Health-Related Quality Of Life, Work Productivity, Employability, and Reduced Healthcare Resource Utilization Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Golimumab: 5-Year Results From 3 Phase III Studies
Abstract Number: 321
Evaluation and Comparison Of Performance Of Different Classification Criteria For Reactive Arthritis
Abstract Number: 322
Ustekinumab Improves Physical Function, Quality Of Life, and Work Productivity Of Patients With Active Psoriatic Arthritis Who Were Methotrexate-naïve Or Previously Treated With Methotrexate Or Anti-Tumor Necrosis Factor Agent:Data From 2 Phase 3, Randomized, Placebo-Controlled Trials
Abstract Number: 323
Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
Abstract Number: 324
Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
Abstract Number: 326
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
Abstract Number: 327
Major Differences In The Pattern Of Joint Swelling and Tenderness In a Large Psoriatic Arthritis Cohort – Results From An Exploratory Hierarchical Cluster Analysis
Abstract Number: 328
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Abstract Number: 329
Health-Related Quality Of Life In Early Psoriatic Arthritis In Comparison With Early Rheumatoid Arthritis. A 5-Year Follow-Up Report From The Swedish Early Psoriatic Arthritis Registry and The Swedish Early Intervention In RA Registry
Abstract Number: 330
Proteomic Profiling Of Synovial Fluid For The Identification Of Psoriatic Arthritis Soluble Biomarkers
Abstract Number: 331
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Abstract Number: 332
Risk Of Cardiovascular Disease Among Patients With Psoriatic Arthritis Compared To Ankylosing Spondylitis (retrospective cohort study)
Abstract Number: 333
Changes In Weight Associated With Tumour Necrosis Factor Inhibition In Psoriatic Arthritis
Abstract Number: 334
The Joint Effect Of Carotid Ultrasound and Preventive Cardiology Referral On Cardiovascular Risk Factor Modification in Psoriatic Arthritis Patients
Abstract Number: 335
Comparing Adalimumab and Etanercept As First Line Agents In Patients With Psoriatic Arthritis. Data From The Rhumadata® Clinical Database and Registry
Abstract Number: 336
Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up
Abstract Number: 337
Fatigue and Work Disability In Psoriatic Arthritis
Abstract Number: 338
Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
Abstract Number: 339
The Association Between Obesity and Radiographic Progression Of Joint Damage Among Patients With Psoriatic Arthritis
Abstract Number: 340
Baseline Characteristics and Treatment Outcomes In Psoriasis Patients With Polyarthritis Or Oligoarthritis
Abstract Number: 341
Impact Of Persistent Minimal Disease Activity On Long-Term Outcomes In Psoriatic Arthritis: Results From 5 Years Of The Long Term Extension Of a Randomized, Placebo-Controlled, Study
Abstract Number: 342
TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Abstract Number: 343
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Abstract Number: 344
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Abstract Number: 345
Prevalence Of Peri-Articular Manifestations (Enthesitis and Dactylitis) and Disease Activity In Psoriatic Arthritis Patients: Impact Of Treatment With TNF Inhibitors In a Real-World Canadian Population
Abstract Number: 346
Rheumatoid Arthritis, a More Severe Disease Than Psoriatic Arthritis? A Comparison Of Disease Activity In Patients With Psoriatic Arthritis and Rheumatoid Arthritis From The Swedish Early Psoriatic Arthritis Registry (SwePsA) and The Swedish Rheumatology Registry For Early RA (SRR)
Abstract Number: 347
Factors Explaining The Discrepancy Between Patient and Physician Global Assessment Of Disease Activity In Psoriatic Arthritis
Abstract Number: 348
Laboratory Abnormalities In Patients With Psoriatic Arthritis Receiving Apremilast, An Oral Phosphodiesterase 4 Inhibitor: Pooled Safety Analysis Of Three Phase 3, Randomized, Controlled Trials
Abstract Number: 349
Serum CTX-I Predicts Systemic Bone Loss At The Hip Over 1 Year In Patients With Early Psoriatic Arthritis
Abstract Number: 350
Cortical Bone Density As Measured By Digital X-Ray Radiogrammetry Correlates with Radiographic Joint Damage In The Hands Within 1 Year In Psoriatic Arthritis
Abstract Number: 351
Psoriatic Arthritis Mutilans: Clinical and Radiographic Definitions. A Systematic Review
Abstract Number: 352
Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis
Abstract Number: 353
Time Interval Between The Onset Of Psoriasis and The Onset Of Psoriatic Arthritis May Define Disease Subsets
Abstract Number: 354
Disease Burden Among Patients With Psoriatic Arthritis Who Have Experienced First Line Tumor Necrosis Factor Inhibitor Regimen Failure In The European Union
Abstract Number: 355
Response To Etanercept With Or Without Methotrexate Combination Therapy In Patients With Psoriatic Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology